Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma

Yamamoto,Yumiko; Hayashi,Yoshihiro; Sakaki,Hideyuki; Murakami,Ichiro

doi:10.3892/mco.2021.2361

Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma

Authors:
- Yumiko Yamamoto
- Yoshihiro Hayashi
- Hideyuki Sakaki
- Ichiro Murakami
View Affiliations

Affiliations: Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Nankoku, Kochi 783‑8505, Japan, Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783‑8505, Japan, Department of Nutritional Sciences for Well‑being Health, Kansai University of Welfare Sciences, Kashiwa, Osaka 582‑0026, Japan
Published online on: August 8, 2021 https://doi.org/10.3892/mco.2021.2361
Article Number: 199
Copyright: © Yamamoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fascin‑1, an actin‑bundling protein, is associated with poor prognosis in patients with various types of human carcinoma. However, research is limited on the role of fascin‑1 in sarcoma. Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare sarcomas derived from the mesenchyme. Although the prognosis of SFT/HPC is generally favorable, fatalities are possible with repeated recurrence and distant metastasis. The current study included a total of 20 Japanese patients, who were diagnosed with SFT/HPC and underwent surgery at Kochi University Hospital from January 2000 to December 2019. The statistical relationship between recurrence and the following variables were examined: Sex, age of onset, tumor origin, tumor size, necrosis, mitosis ≥1/10 high power field (HPF; magnification, x400), Ki‑67 >5% and Fascin‑1. A significant association was determined between recurrence and necrosis, mitosis ≥1/10 HPF (magnification, x400), Ki‑67 >5%, and Fascin‑1 ≥‘strongly positive’ (P<0.05). The results demonstrated that Fascin‑1 immunostaining may be a highly effective and useful evaluation factor for predicting poor prognosis in patients with SFT/HPC, a fatal sarcoma of humans.

View Figures

View References

1	Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS, Chen CL, Zhang L, Wang R, Su F, et al: Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 45:180–185. 2013.PubMed/NCBI View Article : Google Scholar
2	Shukla P, Gulwani HV, Kaur S and Shanmugasundaram D: Reappraisal of morphological and immunohistochemical spectrum of intracranial and spinal solitary fibrous tumors/hemangiopericytomas with impact on long-term follow-up. Indian J Cancer. 55:214–221. 2018.PubMed/NCBI View Article : Google Scholar
3	Davanzo B, Emerson RE, Lisy M, Koniaris LG and Kays JK: Solitary fibrous tumor. Transl Gastroenterol Hepatol. 3(94)2018.PubMed/NCBI View Article : Google Scholar
4	Zhang Q, Qin J, Li Y and Wu T: Primary solitary fibrous tumor of kidney: A case report and literature review. Urol Case Rep. 23:92–94. 2019.PubMed/NCBI View Article : Google Scholar
5	Doyle LA, Vivero M, Fletcher CD, Mertens F and Hornick JL: Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 27:390–395. 2014.PubMed/NCBI View Article : Google Scholar
6	Chmielecki J, Crago AM, Rosenberg M, O'Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA and Meyerson M: Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 45:131–132. 2013.PubMed/NCBI View Article : Google Scholar
7	Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV, Brosjö O, Domanski HA, Larsson O, Sciot R, et al: Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 52:873–886. 2013.PubMed/NCBI View Article : Google Scholar
8	Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Göck T, et al: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 125:651–658. 2013.PubMed/NCBI View Article : Google Scholar
9	Rinaldo L, Xu SCY, Eggers SD, Salomão DR, Chen JJ and Raghunathan A: Rare occurrence of an intraocular choroidal solitary fibrous tumor/hemangiopericytoma. Ocul Oncol Pathol. 4:213–219. 2018.PubMed/NCBI View Article : Google Scholar
10	Tai HC, Chuang IC, Chen TC, Li CF, Huang SC, Kao YC, Lin PC, Tsai JW, Lan J, Yu SC, et al: NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod Pathol. 28:1324–1335. 2015.PubMed/NCBI View Article : Google Scholar
11	Kakkar A, Sakthivel P, Rajeshwari M, Kairo A and Sharma MC: Recurrent sinonasal CD34-negative malignant solitary fibrous tumor diagnosed on STAT6 immunohistochemistry and NAB2-STAT6 fusion. Head Neck Pathol. 14:250–256. 2020.PubMed/NCBI View Article : Google Scholar
12	Penel N, Amela EY, Decanter G, Robin YM and Marec-Berard P: Solitary fibrous tumors and so-called hemangiopericytoma. Sarcoma. 2012(690251)2012.PubMed/NCBI View Article : Google Scholar
13	Thway K, Ng W, Noujaim J, Jones RL and Fisher C: The current status of solitary fibrous tumor: Diagnostic features, variants, and genetics. Int J Surg Pathol. 24:281–292. 2016.PubMed/NCBI View Article : Google Scholar
14	Schmid S, Csanadi A, Kaifi JT, Kübler M, Haager B, Kayser G, Passlick B and Wiesemann S: Prognostic factors in solitary fibrous tumors of the pleura. J Surg Res. 195:580–587. 2015.PubMed/NCBI View Article : Google Scholar
15	Diebold M, Soltermann A, Hottinger S, Haile SR, Bubendorf L, Komminoth P, Jochum W, Grobholz R, Theegarten D, Berezowska S, et al: Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score-a multicenter study. Respir Res. 18(210)2017.PubMed/NCBI View Article : Google Scholar
16	Fountas KN, Kapsalaki E, Kassam M, Feltes CH, Dimopoulos VG, Robinson JS and Smith JR: Management of intracranial meningeal hemangiopericytomas: Outcome and experience. Neurosurg Rev. 29:145–153. 2006.PubMed/NCBI View Article : Google Scholar
17	Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control. 13:264–269. 2006.PubMed/NCBI View Article : Google Scholar
18	Ghose A, Guha G, Kundu R, Tew J and Chaudhary R: CNS hemangiopericytoma: A systematic review of 523 patients. Am J Clin Oncol. 40:223–227. 2017.PubMed/NCBI View Article : Google Scholar
19	Yuzawa S, Nishihara H, Wang L, Tsuda M, Kimura T, Tanino M and Tanaka S: Analysis of NAB2-STAT6 gene fusion in 17 cases of meningeal solitary fibrous tumor/hemangiopericytoma: Review of the literature. Am J Surg Pathol. 40:1031–1040. 2016.PubMed/NCBI View Article : Google Scholar
20	Vogels R, Macagno N, Griewank K, Groenen P, Verdijk M, Fonville J and Kusters B: French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium. Figarella-Branger D, et al: Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: Not (yet) clear. Acta Neuropathol. 137:679–682. 2019.PubMed/NCBI View Article : Google Scholar
21	England DM, Hochholzer L and McCarthy MJ: Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 13:640–658. 1989.PubMed/NCBI View Article : Google Scholar
22	Piri R, Ghaffari A, Azami-Aghdash S, Ali-Akbar YP, Saleh P and Naghavi-Behzad M: Ki-67/MIB-1 as a prognostic marker in cervical cancer-a systematic review with meta-analysis. Asian Pac J Cancer Prev. 16:6997–7002. 2015.PubMed/NCBI View Article : Google Scholar
23	Prueter J, Norvell D and Backous D: Ki-67 index as a predictor of vestibular schwannoma regrowth or recurrence. J Laryngol Otol. 133:205–207. 2019.PubMed/NCBI View Article : Google Scholar
24	Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G, Beltran L, Guzick J and Berney DM: Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: Proving utility for routine assessments. Mod Pathol. 32:1303–1309. 2019.PubMed/NCBI View Article : Google Scholar
25	Go SI, Ko GH, Lee WS, Lee JH, Jeong SH, Lee YJ, Hong SC and Ha WS: The use of CD44 variant 9 and Ki-67 combination can predicts prognosis better than their single use in early gastric cancer. Cancer Res Treat. 51:1411–1419. 2019.PubMed/NCBI View Article : Google Scholar
26	Yamamoto Y, Hayashi Y and Murakami I: Recurrence of solitary fibrous tumor/hemangiopericytoma could be predicted by Ki-67 regardless of its origin. Acta Med Okayama. 74:335–343. 2020.PubMed/NCBI View Article : Google Scholar
27	Hayashi Y, Osanai M and Lee GH: Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases. Cancer Sci. 102:1228–1235. 2011.PubMed/NCBI View Article : Google Scholar
28	Wang CQ, Tang CH, Chang HT, Li XN, Zhao YM, Su CM, Hu GN, Zhang T, Sun XX, Zen Y, et al: Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med. 5:1983–1988. 2016.PubMed/NCBI View Article : Google Scholar
29	Arlt MJ, Kuzmanov A, Snedeker JG, Fuchs B, Silvan U and Sabile AA: Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome. BMC Cancer. 19(83)2019.PubMed/NCBI View Article : Google Scholar
30	Barthelmeß S, Geddert H, Boltze C, Moskalev EA, Bieg M, Sirbu H, Brors B, Wiemann S, Hartmann A, Agaimy A and Haller F: Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol. 184:1209–1218. 2014.PubMed/NCBI View Article : Google Scholar
31	Doyle LA: Sarcoma classification: An update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer. 120:1763–1774. 2014.PubMed/NCBI View Article : Google Scholar
32	Jo VY and Fletcher CD: WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 46:95–104. 2014.PubMed/NCBI View Article : Google Scholar
33	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
34	Macagno N, Vogels R, Appay R, Colin C and Mokhtari K: French CNS SFT/HPC Consortium; Dutch CNS SFT/HPC Consortium. Küsters B, Wesseling P, Figarella-Branger D, et al: Grading of meningeal solitary fibrous tumors/hemangiopericytomas: Analysis of the prognostic value of the marseille grading system in a cohort of 132 patients. Brain Pathol. 29:18–27. 2019.PubMed/NCBI View Article : Google Scholar
35	Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA and Post MD: Fascin is associated with aggressive behavior and poor outcome in uterine carcinosarcoma. Int J Gynecol Cancer. 27:1895–1903. 2017.PubMed/NCBI View Article : Google Scholar
36	Apra C, Alentorn A, Mokhtari K, Kalamarides M and Sanson M: Pazopanib efficacy in recurrent central nervous system hemangiopericytomas. J Neurooncol. 139:369–372. 2018.PubMed/NCBI View Article : Google Scholar
37	Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, et al: Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: A multicentre, single-arm, phase 2 trial. Lancet Oncol. 20:134–144. 2019.PubMed/NCBI View Article : Google Scholar